Most Cited & Viewed

Most Cited & Viewed Papers

Citations Article
 
Introduction to Antibody-Drug Conjugates
by Mark C. Pettinato
 
Immune- and Non-Immune-Mediated Adverse Effects of Monoclonal Antibody Therapy: A Survey of 110 Approved Antibodies
by Brian A. Baldo
 
Alternative Routes of Administration for Therapeutic Antibodies—State of the Art
by Aubin Pitiot, Nathalie Heuzé-Vourc’h and Thomas Sécher
 
Importance and Considerations of Antibody Engineering in Antibody-Drug Conjugates Development from a Clinical Pharmacologist’s Perspective
by Andrew T. Lucas, Amber Moody, Allison N. Schorzman and William C. Zamboni
 
A Review of the Currently Available Antibody Therapy for the Treatment of Coronavirus Disease 2019 (COVID-19)
by Kristin Widyasari and Jinnam Kim
 
Antibodies against Platelet Factor 4 and Their Associated Pathologies: From HIT/HITT to Spontaneous HIT-Like Syndrome, to COVID-19, to VITT/TTS
by Emmanuel J. Favaloro, Leonardo Pasalic and Giuseppe Lippi
 
Development of a Novel Anti-EpCAM Monoclonal Antibody for Various Applications
by Guanjie Li, Hiroyuki Suzuki, Teizo Asano, Tomohiro Tanaka, Hiroyoshi Suzuki, Mika K. Kaneko and Yukinari Kato
 
From Anti-SARS-CoV-2 Immune Response to the Cytokine Storm via Molecular Mimicry
by Darja Kanduc
 
Risk-Based Control Strategies of Recombinant Monoclonal Antibody Charge Variants
by Alain Beck, Christine Nowak, Deborah Meshulam, Kristina Reynolds, David Chen, Dennis B. Pacardo, Samantha B. Nicholls, Gregory J. Carven, Zhenyu Gu, Jing Fang, Dongdong Wang, Amit Katiyar, Tao Xiang and Hongcheng Liu
 
Glycoengineering of Therapeutic Antibodies with Small Molecule Inhibitors
by Shasha Li, Alex J. McCraw, Richard A. Gardner, Daniel I.R. Spencer, Sophia N. Karagiannis and Gerd K. Wagner
Views Article
Immune- and Non-Immune-Mediated Adverse Effects of Monoclonal Antibody Therapy: A Survey of 110 Approved Antibodies
by Brian A. Baldo
Importance and Considerations of Antibody Engineering in Antibody-Drug Conjugates Development from a Clinical Pharmacologist’s Perspective
by Andrew T. Lucas, Amber Moody, Allison N. Schorzman and William C. Zamboni
Construction of a Humanized Artificial VHH Library Reproducing Structural Features of Camelid VHHs for Therapeutics
by Taihei Murakami, Shigefumi Kumachi, Yasuhiro Matsunaga, Miwa Sato, Kanako Wakabayashi-Nakao, Hidekazu Masaki, Ryo Yonehara, Maiko Motohashi, Naoto Nemoto and Masayuki Tsuchiya
Persistent Hyper IgA as a Marker of Immune Deficiency: A Case Report
by Russell J. Hopp and Hana B. Niebur
New Opportunities in Glycan Engineering for Therapeutic Proteins
by Xiaotian Zhong, Aaron M. D’Antona, John J. Scarcelli and Jason C. Rouse
Introduction to Antibody-Drug Conjugates
by Mark C. Pettinato
IgG Avidity Test as a Tool for Discrimination between Recent and Distant Toxoplasma gondii Infection—Current Status of Studies
by Lucyna Holec-Gąsior and Karolina Sołowińska
Glycoengineering of Therapeutic Antibodies with Small Molecule Inhibitors
by Shasha Li, Alex J. McCraw, Richard A. Gardner, Daniel I.R. Spencer, Sophia N. Karagiannis and Gerd K. Wagner
Cryopreservation of Natural Killer Cells Pre-Complexed with Innate Cell Engagers
by Uwe Reusch, Kristina Ellwanger, Ivica Fucek, Thomas Müller, Ute Schniegler-Mattox, Joachim Koch and Michael Tesar
A New Method to Characterize Conformation-Specific Antibody by a Combination of Agarose Native Gel Electrophoresis and Contact Blotting
by Teruo Akuta, Toshiaki Maruyama, Chiaki Sakuma, Masataka Nakagawa, Yui Tomioka, Kevin Entzminger, Jonathan K. Fleming, Ryo Sato, Takashi Shibata, Yasunori Kurosawa, C. J. Okumura and Tsutomu Arakawa
Downloads Article
Introduction to Antibody-Drug Conjugates
by Mark C. Pettinato
Alternative Routes of Administration for Therapeutic Antibodies—State of the Art
by Aubin Pitiot, Nathalie Heuzé-Vourc’h and Thomas Sécher
Immune- and Non-Immune-Mediated Adverse Effects of Monoclonal Antibody Therapy: A Survey of 110 Approved Antibodies
by Brian A. Baldo
A New Method to Characterize Conformation-Specific Antibody by a Combination of Agarose Native Gel Electrophoresis and Contact Blotting
by Teruo Akuta, Toshiaki Maruyama, Chiaki Sakuma, Masataka Nakagawa, Yui Tomioka, Kevin Entzminger, Jonathan K. Fleming, Ryo Sato, Takashi Shibata, Yasunori Kurosawa, C. J. Okumura and Tsutomu Arakawa
The Role of Bispecific Antibodies in Non-Hodgkin’s Lymphoma: From Structure to Prospective Clinical Use
by Rita Tavarozzi and Enrica Manzato
Risk-Based Control Strategies of Recombinant Monoclonal Antibody Charge Variants
by Alain Beck, Christine Nowak, Deborah Meshulam, Kristina Reynolds, David Chen, Dennis B. Pacardo, Samantha B. Nicholls, Gregory J. Carven, Zhenyu Gu, Jing Fang, Dongdong Wang, Amit Katiyar, Tao Xiang and Hongcheng Liu
Persistent Hyper IgA as a Marker of Immune Deficiency: A Case Report
by Russell J. Hopp and Hana B. Niebur
Importance and Considerations of Antibody Engineering in Antibody-Drug Conjugates Development from a Clinical Pharmacologist’s Perspective
by Andrew T. Lucas, Amber Moody, Allison N. Schorzman and William C. Zamboni
Cryopreservation of Natural Killer Cells Pre-Complexed with Innate Cell Engagers
by Uwe Reusch, Kristina Ellwanger, Ivica Fucek, Thomas Müller, Ute Schniegler-Mattox, Joachim Koch and Michael Tesar
Effect of Intrinsic and Extrinsic Factors on the Pharmacokinetics of Antibody–Drug Conjugates (ADCs)
by Iftekhar Mahmood
Back to TopTop